Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-07-20

Clinical Trial Update: A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 trial of ZPL389 in moderate to severe atopic dermatitis was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZPL389

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Atopic Dermatitis | Phase 2 | Status: TERMINATED | Results posted: 2021-07-20